| Item Type | Name |
|
Concept
|
Drug Resistance
|
|
Concept
|
Drug Resistance, Neoplasm
|
|
Concept
|
Drug Resistance, Multiple
|
|
Concept
|
Remission Induction
|
|
Academic Article
|
p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl.
|
|
Academic Article
|
Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL).
|
|
Academic Article
|
BCR/ABL induces multiple abnormalities of cytoskeletal function.
|
|
Academic Article
|
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation.
|
|
Academic Article
|
Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL.
|
|
Academic Article
|
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.
|
|
Academic Article
|
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
|
|
Academic Article
|
Gemcitabine-induced radiation recall.
|
|
Academic Article
|
2-methoxyestradiol alters cell motility, migration, and adhesion.
|
|
Academic Article
|
Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2.
|
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
|
Academic Article
|
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
|
|
Academic Article
|
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.
|
|
Academic Article
|
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways.
|
|
Academic Article
|
Personalized treatment of lung cancer.
|
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
|
Academic Article
|
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
|
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
|
Academic Article
|
Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases.
|
|
Academic Article
|
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
|
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
|
Academic Article
|
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.
|
|
Academic Article
|
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
|
|
Academic Article
|
Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.
|
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
|
Academic Article
|
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
|
|
Academic Article
|
c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury.
|
|
Academic Article
|
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
|
Academic Article
|
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
|
|
Academic Article
|
Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.
|
|
Academic Article
|
Tumor Heterogeneity and Therapeutic Resistance.
|
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
|
Academic Article
|
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
|
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
|
Academic Article
|
Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer.
|
|
Academic Article
|
2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.
|
|
Academic Article
|
Managing Patients With Relapsed Small-Cell Lung Cancer.
|
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
|
Academic Article
|
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.
|
|
Academic Article
|
RLIP: An existential requirement for breast carcinogenesis.
|
|
Academic Article
|
Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.
|
|
Academic Article
|
USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks.
|
|
Academic Article
|
SOX9: The master regulator of cell fate in breast cancer.
|
|
Academic Article
|
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
|
|
Academic Article
|
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM).
|
|
Academic Article
|
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure.
|
|
Academic Article
|
Activating p53 function by targeting RLIP.
|
|
Academic Article
|
Group Behavior and Emergence of Cancer Drug Resistance.
|
|
Academic Article
|
RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells.
|
|
Academic Article
|
Quantifying Cancer: More Than Just a Numbers Game.
|
|
Academic Article
|
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
|
|
Academic Article
|
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
|
|
Academic Article
|
Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy.
|
|
Academic Article
|
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
|
|
Academic Article
|
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.
|
|
Academic Article
|
Addressing Drug Resistance in Cancer: A Team Medicine Approach.
|
|
Academic Article
|
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Prognostic significance of natural products against multidrug tumor resistance.
|
|
Academic Article
|
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance.
|
|
Academic Article
|
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine.
|
|
Concept
|
T-Lymphoma Invasion and Metastasis-inducing Protein 1
|
|
Grant
|
ABNORMALITIES OF MOTILITY OF CML CELLS
|
|
Grant
|
MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
|
|
Grant
|
PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN
|
|
Academic Article
|
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
|
|
Academic Article
|
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
|
|
Academic Article
|
Regression of ovarian cancer xenografts by depleting or inhibiting RLIP.
|
|
Academic Article
|
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.
|
|
Grant
|
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC
|